Lycia Therapeutics (NASDAQ:LYCA) Major Shareholder Venrock Healthcare Capital Par Acquires 1,000 Shares of Stock

Lycia Therapeutics, Inc. (NASDAQ:LYCA) major shareholder Venrock Healthcare Capital Par bought 1,000 shares of the stock in a transaction dated Thursday, October 29th. The stock was bought at an average cost of $26.33 per share, with a total value of $26,330.00. Following the purchase, the insider owned 6,841,233 shares in the company, valued at $180,129,664.89. The trade was a 0.01% increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Venrock Healthcare Capital Par also recently made the following trade(s):

• On Friday, October 30th, Venrock Healthcare Capital Par bought 9,004 shares of Lycia Therapeutics stock. The shares were bought at an average price of $26.28 per share, with a total value of $236,625.12.
• On Wednesday, October 28th, Venrock Healthcare Capital Par purchased 15,000 shares of Lycia Therapeutics stock. The shares were bought at an average price of $25.45 per share, for a total transaction of $381,750.00.
• On Tuesday, October 27th, Venrock Healthcare Capital Par purchased 39,796 shares of Lycia Therapeutics stock. The shares were bought at an average price of $26.62 per share, for a total transaction of $1,059,369.52.
• On Monday, October 26th, Venrock Healthcare Capital Par purchased 1,952,705 shares of Lycia Therapeutics stock. The stock was bought at an average cost of $18.04 per share, for a total transaction of $35,226,798.20.
• On Friday, October 23rd, Venrock Healthcare Capital Par purchased 52,939 shares of Lycia Therapeutics stock. The stock was bought at an average cost of $25.91 per share, for a total transaction of $1,371,649.49.

Lycia Therapeutics Trading Down 4.8%

Shares of LYCA stock opened at $26.40 on Friday. Lycia Therapeutics, Inc. has a fifty-two week low of $22.19 and a fifty-two week high of $36.49.

About Lycia Therapeutics

Lycia Therapeutics, Inc is a biotechnology company developing medicines designed to eliminate disease-causing proteins from cells. The company’s approach is based on lysosome-targeting chimeras, or LYTACs, which are engineered molecules intended to direct extracellular and cell-surface proteins to lysosomes for degradation.

Lycia’s technology is intended to address disease targets that may be difficult to inhibit with conventional drugs, including proteins located outside cells or embedded in cell membranes.